These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15764693)

  • 1. Commentary: Pneumococcal immunization may not be cost-effective in the elderly in developed countries.
    Waugh N
    Int J Epidemiol; 2005 Jun; 34(3):575-6. PubMed ID: 15764693
    [No Abstract]   [Full Text] [Related]  

  • 2. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.
    Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M
    Value Health; 2008; 11(5):898-903. PubMed ID: 18489504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal Vaccines--a Real World Perspective.
    Swaminathan S; Balajee G
    J Assoc Physicians India; 2015 Apr; 63(4 Suppl):25-8. PubMed ID: 26562960
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
    Garattini L; Padula A; Da Costa MR
    Pharmacoeconomics; 2016 Mar; 34(3):221-4. PubMed ID: 26518294
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
    Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
    Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
    Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
    Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
    Davis MM
    Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
    Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
    Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
    Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
    Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pneumococcal vaccine for the elderly--ineffective but cost-efficient?].
    Håkansson J
    Lakartidningen; 2000 Dec; 97(50):5958. PubMed ID: 11188544
    [No Abstract]   [Full Text] [Related]  

  • 15. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumococcal conjugate vaccine: are 3 doses equal to 4 doses?
    Walter EB; Clements DA
    Pediatrics; 2013 Aug; 132(2):e498-9. PubMed ID: 23821696
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
    De Graeve D; Verhaegen J; Ament A; Baltussen R
    Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 19. [Consensus document on pneumococcal vaccination in adults with risk underlying clinical conditions].
    Picazo JJ; González-Romo F; García Rojas A; Peréz-Trallero E; Gil Gregorio P; de la Cámara R; Morató ML; Rodríguez A; Barberán J; Domínguez Hernández V; Linares Rufo M; Jimeno Sanz I; Portolés JM; Sanz Herrero F; Espinosa Arranz J; García-Sánchez V; Galindo Izquierdo M
    Rev Esp Quimioter; 2013 Sep; 26(3):232-52. PubMed ID: 24080892
    [No Abstract]   [Full Text] [Related]  

  • 20. [Costs of pneumococcal infections and cost evaluation of heptavalent conjugate vaccine].
    D'Alessandro D
    Ann Ig; 2002; 14(6 Suppl 7):43-8. PubMed ID: 12638364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.